Photo of Christos S. Mantzoros,  MD, DSc, PhD h.c. mult.

Christos S. Mantzoros, MD, DSc, PhD h.c. mult.

Harvard Medical School

Harvard Medical School
Phone: (617) 667-8630
Fax: (617) 667-8634


cmantzor@bidmc.harvard.edu

Christos S. Mantzoros, MD, DSc, PhD h.c. mult.

Harvard Medical School

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Director Human Nutrition Unit, Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center
  • Chief, Endocrinology, VA Boston Healthcare System

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research program focuses on obesity, diabetes and adipokine biology. My basic research efforts utilize genomics-bioinformatics, animal physiology, and molecular biology studies to elucidate the role of new molecules important in energy homeostasis. My current translational /clinical investigations focus mainly on the role of metabolically important hormones, including leptin, irisin and adiponectin as well as their downstream effectors, on energy homeostasis and metabolic abnormalities. Our work spans the entire spectrum from animal physiology and molecular biology, through observational studies, to physiology and pharmacokinetic interventional proof of concept clinical trials in humans on new therapeutic agents important in the treatment of the above disorders. Recent major contributions by my research group include the elucidation of the physiological role and potential diagnostic and therapeutic utility of leptin in human physiology and pathophysiology. We were the first to prove the role of leptin in mediating the neuroendocrine response to food deprivation in rodents and later in humans, and the first to publish leptin pharmacokinetic studies in humans. We also were the first to publish proof-of-concept studies demonstrating the role of leptin in the etiology and therapy of conditions such as exercise-induced amenorrhea and HIV-induced lipoatrophy. We have recently extended these findings with further randomized clinical trials and combination therapies. Our work has resulted in more than 400 publications that have received more than 20,000 citations. Our work has also resulted in patents for diagnostic and therapeutic applications, has directly contributed to the development of new pharmaceuticals by major pharmaceutical companies, and has contributed to the creation of a new startup, Intekrin, Inc.

Publications

Powered by Harvard Catalyst
  • Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism 2014; 63:188-93. PubMed
  • Dalamaga M, Karmaniolas K, Chamberland J, Nikolaidou A, Lekka A, Dionyssiou-Asteriou A, Mantzoros CS. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. Metabolism 2013; 62:1830-9. PubMed
  • Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 2013; 62:1279-86. PubMed
  • Huffman DM, Augenlicht LH, Zhang X, Lofrese JJ, Atzmon G, Chamberland JP, Mantzoros CS. Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc(1638N/+) female mice. Cancer Prev Res (Phila Pa) 2013; 6:177-87. PubMed
  • Vamvini MT, Aronis KN, Panagiotou G, Huh JY, Chamberland JP, Brinkoetter MT, Petrou M, Christophi CA, Kales SN, Christiani DC, Mantzoros CS. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. 2013; 169:829-34. PubMed
  • Moon HS, Mantzoros CS. Adiponectin and metformin additively attenuate IL1硫-induced malignant potential of colon cancer. Endocr. Relat. Cancer 2013; 20:849-59. PubMed
  • Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 2012; 33:547-94. PubMed
  • Petridou ET, Sergentanis TN, Antonopoulos CN, Dessypris N, Matsoukis IL, Aronis K, Efremidis A, Syrigos C, Mantzoros CS. Insulin resistance: an independent risk factor for lung cancer? Metabolism 2011. PubMed
  • Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 2010. PubMed
  • Nagel JM, Kriegl L, Horst D, Engel J, Gautam S, Mantzoros CS, Kirchner T, Göke B, Kolligs FT. 粒-Catenin is an independent prognostic marker in early stage colorectal cancer. Int J Colorectal Dis 2010; 25:1301-9. PubMed
  • Dalamaga M, Crotty BH, Fargnoli J, Papadavid E, Lekka A, Triantafilli M, Karmaniolas K, Migdalis I, Dionyssiou-Asteriou A, Mantzoros CS. B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece. Cancer Causes Control 2010; 21:1451-9. PubMed
  • Sun Q, Cornelis MC, Kraft P, Qi L, van Dam RM, Girman CJ, Laurie CC, Mirel DB, Gong H, Sheu CC, Christiani DC, Hunter DJ, Mantzoros CS, Hu FB. Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels. Hum Mol Genet 2010; 19:1846-55. PubMed
  • Kotsopoulos J, Tworoger SS, Campos H, Chung FL, Clevenger CV, Franke AA, Mantzoros CS, Ricchiuti V, Willett WC, Hankinson SE, Eliassen AH. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010; 19:938-46. PubMed
  • Fargnoli JL, Sun Q, Olenczuk D, Qi L, Zhu Y, Hu FB, Mantzoros CS. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. 2010; 162:281-8. PubMed
  • Petridou ET, Sergentanis TN, Dessypris N, Vlachantoni IT, Tseleni-Balafouta S, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M, Mantzoros CS. Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. J Clin Oncol 2009; 27:5049-55. PubMed
  • Ligibel JA,Giobbie-Hurder A,Olenczuk D,Campbell N,Salinardi T,Winer EP,Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes Control 2010; 20:1523-8. PubMed
  • Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, Karmaniolas K, Pelecanos N, Tseleni-Balafouta S, Dionyssiou-Asteriou A, Mantzoros CS. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 2009; 20:625-33. PubMed
  • Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 2009; 106:4453-8. PubMed
  • Heidemann C,Schulze MB,Franco OH,van Dam RM,Mantzoros CS,Hu FB. Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation 2008; 118:230-7. PubMed
  • Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 2008; 68:3178-84. PubMed
  • Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, Tseleni-Balafouta S, Mantzoros CS. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr. Relat. Cancer 2008; 15:289-99. PubMed
  • Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2008; 86:s858-66. PubMed
  • Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, Hankinson SE. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007; 92:1510-6. PubMed
  • Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS, . Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 2007; 120:1573-8. PubMed
  • Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007; 92:1041-8. PubMed
  • Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007; 16:308-13. PubMed
  • Petridou ET, Mitsiades N, Gialamas S, Angelopoulos M, Skalkidou A, Dessypris N, Hsi A, Lazaris N, Polyzos A, Syrigos C, Brennan AM, Tseleni-Balafouta S, Mantzoros CS. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology 2008; 73:261-9. PubMed
  • Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005; 97:1688-94. PubMed
Hide